CD25 / IL2RA (Activated Lymphocyte Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone IL2RA/423 ]
|Application ||IF, FC|
|Other Accession||3559, 231367|
|Isotype||Mouse / IgG2a, kappa|
|Other Names||Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2-RA, IL-2R subunit alpha, IL2-RA, TAC antigen, p55, CD25, IL2RA|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD25 / IL2RA (Activated Lymphocyte Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a protein of 55kDa, identified as CD25. It is expressed on activated T- and B-cells and activated monocytes/macrophages. With respect to lymphomas, CD25 is present on malignant cells of Hodgkin�s disease, HTLV-1+ adult T-cell leukemia, cutaneous T-cell lymphoma, and hair cell leukemia. Increased levels of soluble CD25 are observed in the leukemias/lymphomas and inflammatory/ autoimmune diseases. CD25 molecule alone appears to function as a low affinity receptor and associates with CD122 (IL-2R chain, p75) and CD132 (common chain) to form the high affinity IL-2 receptor complex. CD25 antibodies detect three epitope regions, A, B and C. This MAb recognizes the epitope B, which is located at residue 3-104 of CD25 and doe not block IL-2 binding to CD25.
L.A. Rubin, et al, (1985) Hybidoma 4: 91-102. | B. Boutin, et al, (1989) Neuropediatrics 20: 202-206. | T.A. Waldmann, et al, (1989) Annu Rev Biochem 58: 875-911. | T.A. Waldmann, et al, (1995) Blood 86: 4063-4075. | Leukocyte Typing IV (W. Knapp, et al, eds.) Oxford University Press, Oxford, (1989) p. 403-40
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.